CAR-T Cell Therapy for Multiple Myeloma Market Size, Share and Growth Analysis 2025 to 2034

Global CAR-T Cell Therapy for Multiple Myeloma Market is expected to grow at a 27.0 % CAGR during the forecast period for 2023 to 2031.

CAR-T Cell Therapy for Multiple Myeloma Market Size, Share & Trends Analysis Report By Therapy Type (Bb2121, JNJ-68284528 (LCAR-B38M), P-BCMA-101, CAR-CD44V6, Others), By Region, And Segment Forecasts, 2023 to 2031. 

Chimeric Antigen Receptor (CAR) T cell therapy is an innovative treatment that encompasses the reengineering of white blood cells (WBC) of a cancer patient’s to fight the malignant cells by identifying them. CAR-T cell therapy is approved for certain types of blood cancer. The blood cancer type, multiple myeloma affects plasma cells. In multiple myeloma, the malignant cells accrue in the bone marrow (the spongy, soft tissue at the middle of bones), gathering out the normal plasma cells that help fight contamination. These malicious plasma cells then produce M protein, an atypical antibody that offers no advantage to the body and might cause kidney damage, tumors, bone obliteration, and reduced immune function. The high level of M protein in blood denotes the characteristics of multiple myeloma.

The Multiple Myeloma is infrequently curable, but it is an extremely manageable disease that has seen speedy medical development over the past few years. The development of the Multiple Myeloma Research Foundation (MMRF) has improved the research activities to develop the most promising treatments for multiple myeloma. CAR T-cell therapy for multiple myeloma is one advanced immunotherapy to program the immune system to attack cancer. The CAR-T Cell therapy for multiple myeloma market size is expected to reach US$ xx million by 2030, growing at a CAGR of xx% over the forecast period. The rising prevalence of multiple myeloma is anticipated to foster the growth CAR T-cell therapy for multiple myeloma market globally. The presence of potential pipeline drugs to treat multiple myeloma is expected to boost the growth of the market in the coming years. However, high costs associated with CAR T-cell therapy owing to the high cost of research and development activities may hamper the growth of the market substantially over the estimated time frame.

Market Segmentation

Global CAR-T cell therapy for multiple myeloma market is segmented based on therapy type, and country. Based on the therapy type, the CAR T-cell therapy for multiple myeloma market is segmented into JNJ-68284528 (LCAR-B38M), Bb2121, CAR-CD44V6, P-BCMA-101, and others.  Currently, there is no approved CAR- T cell therapy for multiple myeloma in the market. The presence of strong candidates under development stages is expected to accelerate the growth of the market in the coming years. Additionally, various research firms are trying combination therapy to treat multiple myeloma. The recent development in the understanding of immunology has permitted companies to develop new immunotherapeutic methods, that are effective in various cancers, including multiple myeloma. Based on the country, the market is studied across The US, Germany, France, the UK, Italy, and the Rest of the World.

Competitive Landscape

Some Of The key players in the CAR-T Cell Therapy for Multiple Myeloma Market:

• Bluebird bio/Celgene,
• Poseida Therapeutics,
• MolMed S.p.A.,
• Janssen Research & Development,
• Celgene Corporation,
• CARsgen Therapeutics,
• Cartesian Therapeutics,
• Precision BioSciences.

CAR-T Cell Therapy for Multiple Myeloma Market Report Scope :